

Chlamydia Market Report 2034: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight

Chlamydia companies working in the market are Evofem Inc., Clinical Research Management, ActivBiotics Pharma LLC, Warner Chilcott, Meridian Bioscience, & more.

LAS VEGAS, NV, UNITED STATES, January 13, 2025 /EINPresswire.com/ --

DelveInsight's "Chlamydia Market Insights, Epidemiology, and Market Forecast-2034" report offers an in-depth understanding of the Chlamydia, historical and forecasted epidemiology as well as the Chlamydia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Chlamydia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; [Chlamydia Market Forecast](#)

Some of the key facts of the Chlamydia Market Report:

The Chlamydia market size is anticipated to grow with a significant CAGR during the study period (2020-2034).

In 2023, the United States reported approximately 2.165 million new cases of Chlamydia, making it the largest contributor to the total incident population among the seven major markets (7MM), with around 58% of the cases. The EU4 countries and the UK collectively accounted for 33% of the cases, while Japan represented 9% of the total share.

Within the EU4, Germany recorded the highest number of Chlamydia cases (479,000), followed by France (390,000). In contrast, Italy reported the fewest cases, with only 1,395 incidents in 2023.

In 2023, the therapeutic market for Chlamydia across the seven major markets (7MM) was valued at approximately USD 68 million. The market is expected to grow at a compound annual growth rate (CAGR) of 22%, driven by increased disease awareness, improved diagnostic capabilities, and the introduction of emerging therapies.

Among European countries, Germany recorded the largest market size at around USD 6.4 million in 2023, while Italy had the smallest market size, estimated at approximately USD 0.02 million.

Chlamydia is a widespread sexually transmitted infection (STI) caused by the bacterium *Chlamydia trachomatis*. It ranks among the most commonly reported STIs worldwide and frequently goes undiagnosed due to its often asymptomatic nature.

In 2023, the U.S. had the largest market size for Chlamydia among the 7MM (seven major markets), valued at approximately USD 48 million. This figure is projected to grow at a compound

annual growth rate (CAGR) of 23.4%.

Current treatment options primarily involve antibiotics, including Doxycycline, Azithromycin, and Levofloxacin. Azithromycin accounted for the largest market share in 2023, generating approximately USD 22 million in the U.S.

The growth of the Chlamydia market is fueled by increased awareness and education about STIs, advancements in diagnostic technologies, and greater emphasis on sexual health. Factors such as rising infection rates, particularly among younger populations, improved treatment options, public health initiatives, and routine STI testing also drive demand for Chlamydia-related services and products.

The market is expected to expand further during the forecast period, supported by the anticipated introduction of emerging therapies, including the Z007 vaccine and others.

Key Chlamydia Companies: Evofem Inc., Clinical Research Management Inc., ActivBiotics Pharma LLC, Warner Chilcott, Meridian Bioscience Inc., NAMSA, Gen-Probe Incorporated, Binx Health Limited, Pfizer, Melinta Therapeutics Inc., Merck Sharp & Dohme LLC, Endo Pharmaceuticals, Medical Research Council, and others

Key Chlamydia Therapies: EVO100, Chlamydia Infection blockers (CIBs), VPI-201, Salmonella-Based Vaccine, Rifalazil, PRO 2000/5, and others

The Chlamydia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chlamydia pipeline products will significantly revolutionize the Chlamydia market dynamics.

Chlamydia Overview

Chlamydia, caused by *Chlamydia trachomatis*, is the most common bacterial sexually transmitted infection (STI). It primarily affects individuals aged 15–24, with women in this age group experiencing the highest infection rates. Many cases are asymptomatic, increasing the risk of untreated infections leading to complications such as pelvic inflammatory disease, infertility, ectopic pregnancy, epididymitis, and orchitis. Maternal infection can also result in adverse outcomes for newborns, including preterm birth, low birth weight, and respiratory or eye infections.

When symptoms appear, typically two to six weeks after infection, they may include painful urination, abnormal discharge, vaginal pain, or bleeding. Diagnosis relies on clinical evaluation and laboratory testing, with Nucleic Acid Amplification Tests (NAATs) being the preferred method for detecting the bacteria in urine or swab samples.

Routine screening is recommended for sexually active women under 25, pregnant women, and individuals at higher risk of infection to prevent complications. Advances in diagnostics, such as the Aptima Combo 2 Assay and Xpert CT/NG, have enabled extragenital testing (throat and rectum), improving detection and addressing public health needs. Early diagnosis and treatment are essential for effective management and reducing transmission risks.

Get a Free sample for the Chlamydia Market Forecast, Size & Share Analysis Report:
Chlamydia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted

epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Chlamydia Epidemiology Segmentation:

The Chlamydia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Diagnosed Prevalence of Chlamydia in Adults

Diagnosed Prevalence of Chlamydia in Pediatrics

Diagnosed Prevalence of Chlamydia by Types

Diagnosed Prevalence of Chlamydia by Location

Diagnosed Prevalence of Chlamydia by Severity

Chlamydia Marketed Drugs

In 2021, the CDC updated its STI treatment guidelines for chlamydia to address concerns about resistance development. The updated recommendations specify doxycycline 100 mg taken orally twice daily for 7 days as the preferred treatment. Alternative options include a single oral dose of azithromycin 1 g or levofloxacin 500 mg taken orally once daily for 7 days. Additionally, a delayed-release (DR) formulation of doxycycline is available, designed to reduce the pill burden and minimize gastrointestinal side effects for patients.

Chlamydia Therapies

EVO100, Chlamydia Infection blockers (CIBs), VPI-201, Salmonella-Based Vaccine, Rifalazil, PRO 2000/5, and others

Chlamydia Key Companies

Evoform Inc., Clinical Research Management Inc., ActivBiotics Pharma LLC, Warner Chilcott, Meridian Bioscience Inc., NAMSA, Gen-Probe Incorporated, Binx Health Limited, Pfizer, Melinta Therapeutics Inc., Merck Sharp & Dohme LLC, Endo Pharmaceuticals, Medical Research Council, and others

Discover more about therapies set to grab major Chlamydia market share @ [Chlamydia Treatment Landscape](#)

Chlamydia Market Outlook

Chlamydia trachomatis is the most commonly diagnosed bacterial sexually transmitted infection (STI) worldwide. The number of cases has risen over the past decade due to improved diagnostic sensitivity and increased screening efforts. Genital infections are asymptomatic in 50–88% of men and women, with about 46% clearing spontaneously within a year. However, persistent infections can lead to severe complications such as pelvic inflammatory disease, ectopic pregnancy, and tubal infertility in women, as well as epididymitis and epididymo-orchitis in men. Although infections can occur at any age, they are most common in individuals under 25, with peak diagnosis rates observed in women aged 16–19 and men aged 20–24.

For many years, azithromycin was the preferred treatment for *C. trachomatis* infections. However, extensive use has led to increased resistance, with studies showing higher treatment failure rates compared to doxycycline. In response, the CDC updated its STI treatment guidelines in 2021, recommending doxycycline 100 mg taken orally twice daily for 7 days as the first-line

therapy.

To address antimicrobial resistance, programs like antimicrobial stewardship promote the responsible use of antibiotics. Alternative treatment options include azithromycin 1 g in a single oral dose or levofloxacin 500 mg taken daily for 7 days. A delayed-release (DR) formulation of doxycycline, dosed at 200 mg once daily for 7 days, is available to reduce pill burden and gastrointestinal side effects, though it is more expensive. Ofloxacin (but not all quinolones) is also effective, and erythromycin serves as a backup for patients unable to take other treatments.

Antibiotics remain the only available treatment for chlamydia. However, high reinfection rates highlight the urgent need for vaccine development. Progress in this area faces challenges, including the difficulty of replicating successful mouse model results in non-human primates. Over the past 30 years, only 12 attempts have been made to achieve this replication. Despite these hurdles, several vaccines are in the preclinical stage, with notable players such as Ziphius Vaccines and Abera Bioscience advancing development.

Scope of the Chlamydia Market Report

Study Period: 2020–2034

Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

Key Chlamydia Companies: Evofem Inc., Clinical Research Management Inc., ActivBiotics Pharma LLC, Warner Chilcott, Meridian Bioscience Inc., NAMSA, Gen-Probe Incorporated, Binx Health Limited, Pfizer, Melinta Therapeutics Inc., Merck Sharp & Dohme LLC, Endo Pharmaceuticals, Medical Research Council, and others

Key Chlamydia Therapies: EVO100, Chlamydia Infection blockers (CIBs), VPI-201, Salmonella-Based Vaccine, Rifalazil, PRO 2000/5, and others

Chlamydia Therapeutic Assessment: Chlamydia current marketed and Chlamydia emerging therapies

Chlamydia Market Dynamics: Chlamydia market drivers and Chlamydia market barriers

Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

Chlamydia Unmet Needs, KOL's views, Analyst's views, Chlamydia Market Access and Reimbursement

To know more about Chlamydia companies working in the treatment market, visit @ [Chlamydia Clinical Trials and Therapeutic Assessment](#)

Table of Contents

1. Chlamydia Market Report Introduction
2. Executive Summary for Chlamydia
3. SWOT analysis of Chlamydia
4. Chlamydia Patient Share (%) Overview at a Glance

5. Chlamydia Market Overview at a Glance
6. Chlamydia Disease Background and Overview
7. Chlamydia Epidemiology and Patient Population
8. Country-Specific Patient Population of Chlamydia
9. Chlamydia Current Treatment and Medical Practices
10. Chlamydia Unmet Needs
11. Chlamydia Emerging Therapies
12. Chlamydia Market Outlook
13. Country-Wise Chlamydia Market Analysis (2020–2034)
14. Chlamydia Market Access and Reimbursement of Therapies
15. Chlamydia Market Drivers
16. Chlamydia Market Barriers
17. Chlamydia Appendix
18. Chlamydia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

Chlamydia Pipeline

"Chlamydia Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Chlamydia market. A detailed picture of the Chlamydia pipeline landscape is provided, which includes the disease overview and Chlamydia treatment guidelines.

Chlamydia Epidemiology

DelveInsight's 'Chlamydia Epidemiology Forecast to 2034' report delivers an in-depth understanding of the disease, historical and forecasted Chlamydia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight

Adalimumab Biosimilar Market | Arbovirus Infection Market | Artificial Pancreas Device System Market | Dental Equipment Market | Gluten Sensitivity Market | Hypothyroidism Market | Inflammatory Bowel Disease Market | Mayus Kinase Jak Inhibitors Market | Mild Dry Eye Market | Mucopolysaccharidosis Market | Oncolytic Virus Cancer Therapy Market | Pyoderma Gangrenosum Market | Transdermal Drug Delivery Devices Market | Intrathecal Pumps Market | Hedgehog Pathway Inhibitors Market | Yellow Fever Market | Laryngeal Cancer Market | Female Infertility Market | Gender Dysphoria Market | Chronic Brain Damage Market | Spain Healthcare Outlook Market | Malignant Fibrous Histiocytoma Market | Asthma Diagnostic Devices Market | Chronic Obstructive Pulmonary Disease Treatment Devices Market | Airway Management Devices Market | Cough Assist Devices Market | Pulse Oximeters Market | Hemodialysis Catheter Devices Market | Chronic Spontaneous Urticaria Market | Gender Dysphoria Market | Germany Healthcare Outlook | Biopsy Devices Pipeline Insight | Bacterial Conjunctivitis Market | Infliximab Biosimilar Insight | Eosinophilic Asthma Market | Cushing Syndrome Market | Functional Dyspepsia Market | Peripherally Inserted Central Catheters (PICC) Devices Market

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Kritika Rehani

DelveInsight Business Research LLP

+1 469-945-7679

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/776504236>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.